The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ELCC 2021 | KEYNOTE-407: pembrolizumab plus chemo improves OS and PFS in NSCLC
Sanjay Popat, BSc, MBBS, FRCP, PhD, The Royal Marsden NHS Foundation Trust, London, UK, discusses updated data from the KEYNOTE-407 trial (NCT02775435) investigating first-line pembrolizumab plus chemotherapy for patients with advanced squamous non-small cell lung cancer (NSCLC). At three years of follow-up, the study reported a median overall survival (OS) of 17.2 months and an OS rate of 29.7% in the pembrolizumab plus chemotherapy arm, versus a median OS of 11.6 months and an OS rate of 18.2% in the placebo plus chemotherapy arm. This video was recorded at the virtual European Lung Cancer Congress (ELCC) 2021.
